Acute Myeloid Leukemia | Topics

FDA Lifts Partial Clinical Hold on Early-Phase Study of KO-539 in AML
January 24, 2022

The phase 1b KOMET-001 trial, examining the use of KO-539 in patients with relapsed or refractory acute myeloid leukemia, will continue following authorization from the FDA.

CA-4948 Yields Promising Clinical Activity in R/R AML/MDS; Initial Findings Read Out for CI-8993 in R/R Solid Tumors
January 07, 2022

Treatment with CA-4948 monotherapy yielded positive safety data and efficacy for patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome; CI-8993 also appeared to show promise in patients with relapsed/refractory solid tumors.

Outcomes With the CD3/CD123 Bispecific Antibody APVO436 Appear Unaffected by CRS and Interventional Steroids in AML/MDS
January 05, 2022

CD123- and CD3-engaging bispecific antibody, APVO436, caused cytokine release syndrome that could be managed through the use of steroids in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

FDA Grants Natural Killer Cell Therapy, CYNK-001, Fast Track Designation for Acute Myeloid Leukemia
January 04, 2022

CYNK-001 was recently granted fast track designation by the FDA for the treatment of patients with acute myeloid leukemia.

KO-539 Plus Targeted Therapies Yields Synergistic Activity for KMT2A-Rearranged and NPM1-Mutated AML Models
January 04, 2022

Preclinical evidence supports further research in combining a menin inhibitor plus targeted therapies, as this may result in superior efficacy for patients with KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.

No Significant Differences Seen Between Outpatient and Inpatient Neutropenia Management for Pediatric Acute Myeloid Leukemia
December 27, 2021

A cohort study did not identify strong associations between outpatient or inpatient neutropenia management and increased bacteremia incidence, treatment delays, or worse health-related quality of life for pediatric patients with acute myeloid leukemia.

Sustained Survival Benefit Seen With Oral Azacitidine as Maintenance Therapy for AML in First Remission
December 15, 2021

Maintenance oral azacitidine produced a sustained survival benefit over placebo for patients with acute myeloid leukemia in first remission.

Recruiting Has Begun in Trial to Determine Magrolimab Efficacy in R/R AML
December 14, 2021

A phase 2 study has begun recruiting patients with relapsed/refractory acute myeloid leukemia to test the efficacy of magrolimab.

Gemtuzumab Ozogamicin Plus Chemo Improves Outcomes in Pediatric KMT2A-Rearranged AML
December 01, 2021

Pediatric patients with KMT2A-rearranged acute myeloid leukemia who were treated with gemtuzumab ozogamicin plus standard chemotherapy experienced improved event-free survival and a reduced relapsed risk.

Quizartinib/Chemo Combo Shows Superiority Over Chemo Alone in Adults with Newly Diagnosed FLT3-ITD–Positive AML
November 22, 2021

Investigators announced positive topline results for the phase 3 QuANTUM-First trial, assessing the use of quizartinib plus chemotherapy for adult patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.